Adalimumab in Severe and Acute Sciatica

Summary

The purpose of this study is to determine whether adalimumab (a TNF-alpha inhibitor) is effective in the treatment of severe and acute sciatica.

Timeline

Start

2005-05

Primary completion

2008-01

Completion

2008-06

Outcome

Met primary endpoint

paper Over time, the course of leg pain was more favorable in the adalimumab group than in the placebo group (P = 0.002). PMID 20506391 ↗

Publications

• Genevay S, Viatte S, Finckh A, Zufferey P, Balague F, Gabay C. Adalimumab in severe and acute sciatica: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010 Aug;62(8):2339-46. doi: 10.1002/art.27499.

Drugs

Indications